32 results about "Re-epithelialization" patented technology

Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 protein and/or a galectin-7 protein are also provided.

The invention is a discrete patch suitable for use in the treatment of a viral lesion, which patch includes a backing layer and an adhesive layer, where the adhesive layer is substantially free of hydrocolloid particles, and the patch has a thickness ranging from about 10 microns to about 1,500 microns and is substantially free of topical anti-acne agents, and methods for treating viral lesions where a discrete patch of the invention is applied to a viral lesion and maintained in contact therewith for a time effective to substantially complete re-epithelialization of the lesion.

The invention discloses a fibrin hydrogel stent loaded with human umbilical cord mesenchymal stem cells and application of the fibrin hydrogel stent, and belongs to the technical field of hydrogel. The human umbilical cord mesenchymal stem cells are cultured until the density reaches 70 percent to 80 percent; treatment is performed by using a cell digestion solution, and the human umbilical cord mesenchymal stem cells are resuspended by using a fibrin raw solution to obtain a human umbilical cord mesenchymal stem cell-fibrin raw solution mixed solution; and a thrombin solution is added into the mixed solution to obtain the fibrin hydrogel stent loaded with the human umbilical cord mesenchymal stem cells. Through combined application of the fibrin hydrogel stent and the human umbilical cordmesenchymal stem cells, the healing speed of a wound is obviously accelerated; the re-epithelialization is promoted; the inflammatory response is inhibited; the angiogenesis is promoted; the scar formation is reduced; the wound is healed to be close to normal skin tissues to a greater extent; and the treatment requirement is met.

A wound-healing and hemostatic sponge of squid ink polysaccharide/chitosan, a preparation method and use thereof are provided. The sponge comprises squid ink polysaccharide and chitosan as carriers and calcium chloride as an initiator for blood coagulation, and the wound-healing and hemostatic sponge of squid ink polysaccharide/chitosan is achieved via a lyophilization technology. Particularly, the preparation method comprises slowly adding a squid ink polysaccharide solution to a chitosan solution to form a uniformly mixed solution, adding a calcium chloride solution to the uniformly mixed solution, forming a gel followed by the gel being frozen and then lyophilized, and achieving the product. The wound-healing and hemostatic sponge has a good absorbing-errhysis effect, a good pro-coagulant effect, fast hemostasis and a complete hemostatic effect, without secondary re-hemorrhage. Moreover, the wound-healing and hemostatic sponge can promote wound healing, re-epithelialization and repair of epidermis and dermis, with strong wound-healing ability, good biocompatibility, weak toxic side effects and irritation, belonging to a novel wound-healing and hemostatic material. Moreover, the preparation method is reliable, fast, and low cost.

Disclosed are methods of polarizing macrophages to exhibit M2 phenotype, including introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with the gingiva-derived mesenchymal stem cells. Also disclosed are methods of promoting cutaneous wound healing including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls. Also disclosed are methods for attenuating contact hypersensitivity in a patient, the methods including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitity.

The invention is a discrete patch suitable for use in the treatment of a viral lesion, which patch includes a backing layer and an adhesive layer, where the adhesive layer is substantially free of hydrocolloid particles, and the patch has a thickness ranging from about 10 microns to about 1,500 microns and is substantially free of topical anti-acne agents, and methods for treating viral lesions where a discrete patch of the invention is applied to a viral lesion and maintained in contact therewith for a time effective to substantially complete re-epithelialization of the lesion.

The invention relates to a process for obtaining a cellular sprinkling compound and to the respective method of application to provide a therapeutic treatment for skin injuries, based on the implantation, by sprinkling and/or spraying, of human mesenchymal stem cells and microvascular endothelial cells that have been pre-expanded in vitro and resuspended in a regenerative solution for cellular implantation of biocompatible biomaterials. The solution is formed by blood plasma rich in growth factors obtained from the patient to be treated and, in some cases, by medical-grade type I collagen and by medical-grade hyaluronic acid, which potentiates the regeneration, re-epithelialization, and reconstruction of skin tissue.

Compositions for topical application based on natural products, specifically dried pulverized plants suspended in bees honey, in which the ingredients are combined in proportions predetermined to provide three different types of preparations to be applied at various stages of repair and regeneration of injured tissues. The application of the compositions shortens the stages of healing in the treatment of acute and chronic injuries of any degree of depth and breadth, and of any etiology.

The properties of the preparations include an hemorheological and systemic vascular activity which extends for a certain period even after the end of topical treatment.

A method of healing a wound including contacting a wound edge with a tropoelastin or elastin derived peptide in conditions for enabling a sustained contact of the tropoelastin with the wound edge for a time period for enabling re-epithelialization of the wound.

The invention relates to the technical field of sponge scaffolds, in particular to a preparation method of a salidroside-collagen sponge scaffold and application thereof in skin wound healing. The preparation method of the salidroside-collagen sponge scaffold comprises the steps of I, preparing a collagen mixture; II, injecting into a culture plate; and III, lyophilizing. According to the preparation method, collagen is used as a natural material and drug carrier to construct the salidroside-collagen sponge scaffold, and the salidroside-collagen sponge scaffold prepared has the advantages of high interconnectivity and porosity, has no influence on drug release, and has good skin wound healing effect. The salidroside-collagen sponge scaffold was confirmed by animal experiments to have goodeffect on skin wound healing, references can be provided for basic research and clinical application of wound healing, the scaffold has the best re-epithelialization effect, and therefore, the salidroside-collagen sponge scaffold can promote skin wound healing and skin re-epithelialization.

Pharmaceutical compositions for the treatment of bacterial skin infections, burns and wounds are disclosed. The pharmaceutical composition comprises an active ingredient, preferably mupirocin; a biopolymer, preferably chitosan, having a molecular weight in the range of 250,000 Da to 600,000 Da, and having a degree of deacetylation of not less than 80%; hydrolyzed collagen, preferably Type I, having a molecular weight in the range of 3 kDa to 6 kDa, and an ointment base comprising an emulsifier, a diol, and a solubilizing agent. The present invention has better stability than existing ointments, which achieves skin healing and reepithelization faster than existing treatments, thereby shortening hospitalization time.

As described herein, leptin treatment significantly increased wound contraction and epithelial regeneration while reducing granulation tissue and wound area, consistent with a healing augmentation effect. Specifically, in leptin-treated wounds, the inventor found increased expression of smooth muscle-actin (-SMA) and collagens I, III and IV. Taken together, the inventor's results indicate that a major functional theme for the accelerated wound healing action of leptin consists of the acute, local induction of genes whose expression are critical for repair and contraction. Thus, the invention relates to methods and compositions for the promotion and/or acceleration of wound repair, re-epithelialization, wound contraction and decrease of granulation tissue by administering leptin to the subject, as well as methods for studying this process.

A formulation of a discrete liquid patch for the treatment of cold sores or viral lesions, including a combination of the adhesive layer and an active compound/ingredient such as antiviral agents, and/or amino acids, and/or minerals/vitamins. The adhesive layer of the discrete patch is substantially free of hydrocolloid particles. The adhesive layer does not include any backing layer to maintain the compliance of the patch with a thickness ranging from 5 microns to 1,300 microns. Wherein, the discrete patch of the invention is configured to apply to a viral lesion to maintain in contact therewith for a time effective to substantially complete re-epithelialization of the lesion.

The invention discloses a novel non-woven fabric wound dressing and a preparation method and application thereof. The wound dressing is prepared from modified polyester fibers, modified chitosan fibers and modified calcium alginate fibers through a spunlace or needling non-woven processing procedure, wherein the modified polyester fibers are 20-40 parts by mass, the modified chitosan fibers are 10-20 parts by mass, and the modified calcium alginate fibers are 10-40 parts by mass; the modified polyester fibers contain 5-10 wt% of nano silver, the modified chitosan fibers contain 0.1-1 wt% of copper ions, and the modified calcium alginate fibers contain 0.1-2 wt% of zinc ions; and the invention also discloses the application of the novel non-woven fabric wound dressing in skin wound covering dressings. According to the wound dressing, the antibacterial effect can penetrate through the whole wound healing process, the effects of promoting angiogenesis, promoting reepithelization and the like can be achieved, and therefore the effective promoting or auxiliary accelerating effect is achieved in the wound healing process.

The invention relates to the technical field of blood products, and discloses a preparation method of leukocyte-rich and platelet-rich plasma (L-PRP), comprising the steps of sampling blood and preparing L-PRP; the invention also discloses an application of the L-PRP in wound treatment. The platelet content of the prepared L-PRP is about 4 times that of whole blood, the L-PRP is rich in leukocytes and interleukin 6 (IL-6), and it is found that the L-PRP can promote keratinocyte migration and accelerate wound reepithelization by up-regulating the IL-6 transcriptional level and activating signal transduction and transcriptional activation protein 3 (STAT3); according to the prepared L-PRP and the research on the L-PRP, classification and application scenes of platelet-rich plasma (PRP) are refined, a new mechanism of promoting wound healing by the L-PRP is found, a new solution is provided for clinically solving refractory wounds, and the L-PRP has important clinical practical significance.